Gwen Cousins, MD

10/22/2020

Support your surgeon.  Speak out against unequal Medicare cuts for surgeons. 

American College of Surgeons

11/22/2019

Songs to avoid playing in the OR. You wouldn’t want to hear “Blinded by the light” if you were having eye surgery. Find out other songs to avoid in the article.

Chief medical editor Larry E. Patterson, MD, loves playing music in the operating room…unless it’s from this list of 10 worst songs for eye surgery.

11/13/2019

Screening for choroidal melanoma is important for eyes with pigmented lesions. Learn about which features are risk factors for developing ocular melanoma.

sformation of choroidal nevus into melanoma. Results: The median patient age was 62.5 years and Caucasian race in 3167 (95%). The choroidal nevus demonstrated median basal diameter of 4.0 mm and thickness of 1.4 mm. Imaging included optical coherence tomography (OCT) showing subretinal fluid (SRF) i...

11/02/2019

Check out this retina challenge diagnosis from ASRS.
https://www.asrs.org/clinical/spotlight-case/spotlight-case-a-case-of-eye-scites

11/02/2019

Retinal vein occlusion. https://www.instagram.com/p/B2tt4avBlMg/?utm_source=ig_web_button_share_sheet

11/02/2019

x linked retinoschisis

11/02/2019

A drug widely prescribed for a bladder condition for decades, now appears to be toxic to the retina, the light sensing tissue at the back of the eye that allows us to see.

10/31/2019

We are getting close to treatment for geographic atrophy associated with dry macular degeneration!

Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of

10/23/2019

Bausch + Lomb announced the U.S. launch of PreserVision AREDS 2 Formula minigel eye vitamins. The new minigels will replace the currently offered PreserVision AREDS 2 Formula soft gels, offering pa

10/17/2019

Good news for patients with geographic atrophy, a type of dry macular degeneration that currently has no available treatment that is approved by the FDA. Retina Associates New Orleans is currently enrolling patients into the Apellis pharmaceutical clinical trial to receive this novel treatment. If you are interested in learning more about this treatment please contact us at www.retinaassociates.org

Patients treated with the complement inhibitor pegcetacoplan (APL-2, Apellis Pharmaceuticals) showed significant reduction in growth of geographic atrophy (GA) lesions compared with sham-treated eyes, according to 1-year data from the phase 2 FILLY study.1 The trial was a multicenter, randomized, si...